All In Biotech

Drug Trial Radar · NCT01951209

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

Prospective Pilot Study of the Effect of Rifaximin on B-Cell Dysregulation in Cirrhosis Due to Chronic Hepatitis C Infection

Last checked: Nov 20, 2026Latest source record: Mar 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

13

Actual

Start

Nov 17, 2016

Primary completion

Nov 17, 2016

Study completion Jun 12, 2017

Sponsor

Lead sponsor
David E. Kaplan, MD MScFederal agency
Sponsor type
Federal agency
Collaborators
Bausch Health Americas, Inc.
First posted
Sep 26, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hepatitis C is the leading cause of chronic liver disease and cirrhosis in United States veterans. Cirrhosis is associated with impaired antibody responses and increased risk of bacterial infections. We have recently identified that cirrhosis is associated with abnormalities of memory B-cells, cells that make antibodies and help protect against bacterial infections. We have identified that chemicals associated with gut bacteria might play a role in causing these B-cell abnormalities. It is well known that gut bacteria have increased access to the blood in individuals with cirrhosis, a process called bacterial translocation. We hypothesize that reducing bacteria counts in the gut by using poorly-absorbed antibiotics (also known as selective gut decontamination) will partially reverse losses of memory B-cells in cirrhosis by reducing bacterial translocation.

Conditions

  • Liver Cirrhosis
  • Chronic Hepatitis C

Interventions

  • RifaximinDrug

    550mg orally twice daily for 12 weeks

  • PlaceboDrug

    Matched placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in CD27+ B-cell frequencyTime frame: Week 0 (Baseline) to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Philadelphia VA Medical Center

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.